Harrow’s (HROW) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Harrow (NASDAQ:HROW) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $57.00 target price on the stock.

Separately, B. Riley reduced their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

Harrow Stock Up 3.0 %

Shares of NASDAQ:HROW opened at $28.09 on Tuesday. Harrow has a 52 week low of $9.86 and a 52 week high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The company has a market capitalization of $1.00 billion, a PE ratio of -29.88 and a beta of 0.69. The company has a 50 day moving average price of $29.67 and a two-hundred day moving average price of $38.48.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in Harrow during the fourth quarter worth $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Harrow by 89.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company’s stock worth $2,078,000 after acquiring an additional 29,262 shares in the last quarter. Two Sigma Advisers LP raised its position in Harrow by 30.4% during the fourth quarter. Two Sigma Advisers LP now owns 38,200 shares of the company’s stock worth $1,282,000 after acquiring an additional 8,900 shares in the last quarter. Two Sigma Investments LP raised its position in Harrow by 483.2% during the fourth quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock worth $5,044,000 after acquiring an additional 124,574 shares in the last quarter. Finally, Rafferty Asset Management LLC bought a new stake in Harrow during the fourth quarter worth $270,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.